49 related articles for article (PubMed ID: 8753141)
1. Human prolactinomas in cell culture: structure-function correlation and indication of early relapse.
Wang CJ; Howng SL
Kaohsiung J Med Sci; 1996 Jul; 12(7):394-9. PubMed ID: 8753141
[TBL] [Abstract][Full Text] [Related]
2. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
3. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
4. Annulate lamellae in prolactin-secreting pituitary adenomas.
Mori H; Mori S; Saitoh Y; Koizumi K; Aono T
Acta Neuropathol; 1983; 61(1):10-4. PubMed ID: 6624383
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
6. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
7. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
8. A light and electron microscopical study of pituitary adenomas.
Stefăneanu L; Taşcă C; Coculescu M
Endocrinologie; 1981; 19(4):243-8. PubMed ID: 7323648
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
11. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
12. Surgical management considerations in cystic prolactinomas-a single center case series.
Nevzati E; Chatain GP; Carr SB; Lillehei KO; Kerr JM
Endocrine; 2020 Jan; 67(1):58-66. PubMed ID: 31773633
[TBL] [Abstract][Full Text] [Related]
13. Hereditary pituitary prolactinomas: a new rat model.
Chedid A; Hoversland RC; Chejfec G; McCune SA; Jurin RR; Evans EE
Acta Endocrinol (Copenh); 1988 Dec; 119(4):535-42. PubMed ID: 3059738
[TBL] [Abstract][Full Text] [Related]
14. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatment of prolactinomas--our experience.
Gnjidić Z; Kudelić N; Sajko T; Malenica M; Stipić D; Rotim K
Coll Antropol; 2014 Jun; 38(2):571-6. PubMed ID: 25144990
[TBL] [Abstract][Full Text] [Related]
16. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
19. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up.
Feigenbaum SL; Downey DE; Wilson CB; Jaffe RB
J Clin Endocrinol Metab; 1996 May; 81(5):1711-9. PubMed ID: 8626821
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of anaemia associated with prolactin-secreting pituitary tumours in men.
Iglesias P; Castro JC; Díez JJ
Int J Clin Pract; 2011 Jun; 65(6):669-73. PubMed ID: 21564439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
